Brazil plans to buy 60 million doses of the single-shot COVID-19 vaccine developed by China's CanSino Biologics for delivery in the third and fourth quarters of this year, Reuters news agency reported on Wednesday.
According to a negotiation document reviewed by Reuters, a ministry official signed a letter of intent on 4 June 2021 to purchase the vaccine doses with Belcher Farmaceutica do Brasil, a Brazilian pharmaceutical company that represents CanSino in Brazil.
This vaccine, trade-named Convidecia and developed by CanSino together with a research institute linked to the Chinese military, will cost USD17 per dose, the document said.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer